There's a scientific breakthrough in your medicine cabinet. But how did it get there?
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
All content for Making Medicine is the property of Incubate Coalition and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
There's a scientific breakthrough in your medicine cabinet. But how did it get there?
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
Inside Congress: Senator Thom Tillis on Drug Pricing, IP, and the Future of Innovation
Making Medicine
29 minutes
1 month ago
Inside Congress: Senator Thom Tillis on Drug Pricing, IP, and the Future of Innovation
In this episode of Making Medicine, host John Stanford sits down with Senator Thom Tillis, the first sitting U.S. Senator to join the show. Tillis opens up about his relationship with President Trump, the impact of Most Favored Nation (MFN) drug pricing on U.S. innovation, and the forces shaping America’s biotech competitiveness. They discuss why predictable intellectual property and regulatory frameworks are critical for investment and how the U.S. can maintain a leading edge in life sciences. Don’t miss Tillis’s insights on why he chose not to seek reelection and what might come next for his career. This is a must-listen for anyone interested in biotech policy, life sciences innovation, or U.S. global competitiveness.
What do you think about MFN-style pricing in the U.S.? How can policymakers best support biotech innovation? Which part of the life sciences ecosystem do you think needs the most attention right now?
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Timestamps: 0:00 Introduction to Making Medicine and Senator Thom Tillis 1:12 Tillis joins the podcast as the first sitting Senator 2:05 Early career and motivations in public service 4:20 Relationship with President Trump and MFN drug pricing 7:35 Potential impacts of MFN-style controls on U.S. innovation 10:10 America’s global biotech competitiveness and China 13:50 Importance of IP and regulatory predictability for investment 16:25 Reflections on policy successes and challenges 18:40 Decision not to seek reelection 20:30 What’s next for Senator Tillis 22:00 Key takeaways on biotech policy and U.S. innovation 24:15 Closing thoughts and call to action
DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
Making Medicine
There's a scientific breakthrough in your medicine cabinet. But how did it get there?
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
